A mathematical model of combination therapy using the EGFR signaling network.

An increasing awareness of the significance of abnormal signal transduction in tumors and the concomitant development of target-based drugs to selectively modulate aberrantly-activated signaling pathways has given rise to a variety of promising new strategies in cancer treatment. This paper uses mathematical modeling to investigate a novel type of combination therapy in which multiple nodes in a signaling cascade are targeted simultaneously with selective inhibitors, pursuing the hypothesis that such an approach may induce the desired signal attenuation with lower doses of the necessary agents than when one node is targeted in isolation. A mathematical model is presented which builds upon previous theoretical work on EGFR signaling, simulating the effect of administering multiple kinase inhibitors in various combinations. The model demonstrates that attenuation of biochemical signals is significantly enhanced when multiple upstream processes are inhibited, in comparison with the inhibition of a single upstream process. Moreover, this enhanced attenuation is most pronounced in signals downstream of serially-connected target points. In addition, the inhibition of serially-connected processes appears to have a supra-additive (synergistic) effect on the attenuation of downstream signals, owing to the highly non-linear relationships between network parameters and signals.

[1]  Reinhart Heinrich,et al.  Mathematical models of protein kinase signal transduction. , 2002, Molecular cell.

[2]  B. Kholodenko,et al.  Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades , 2004, The Journal of cell biology.

[3]  C. Langer,et al.  Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. , 2004, International journal of radiation oncology, biology, physics.

[4]  M. Mimeault,et al.  Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines , 2003, International journal of cancer.

[5]  G. Fontanini,et al.  Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  P. Bunn,et al.  ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. , 2002, Seminars in oncology.

[7]  Katherine C. Chen,et al.  Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. , 2003, Current opinion in cell biology.

[8]  D. Lauffenburger,et al.  Computational modeling of the EGF-receptor system: a paradigm for systems biology. , 2003, Trends in cell biology.

[9]  N. Saijo,et al.  Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells , 2004, International journal of cancer.

[10]  M. Ranson.  ZD1839 (Iressa): for more than just non-small cell lung cancer. , 2002, The oncologist.

[11]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[12]  B. Kholodenko,et al.  Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor* , 1999, The Journal of Biological Chemistry.

[13]  P. Harari,et al.  Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? , 2004, International journal of radiation oncology, biology, physics.

[14]  E. Petricoin,et al.  Clinical proteomics: personalized molecular medicine. , 2001, JAMA.